NCT04985955

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3

A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin as a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved Interventions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Tofacitinib	Tofacitinib tablet will be administered orally.

Timeline

• Start date: 2021-07-30
• Primary completion: 2021-09-21
• Completion: 2021-09-21
• First posted: 2021-08-02
• Last updated: 2025-02-03

Locations

1 site across 1 country: Belgium